Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Is Skyrocketing Today

By Keith Speights - Updated Jan 27, 2021 at 11:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech reported encouraging early results for one of its experimental COVID-19 therapies.

What happened

Shares of Sorrento Therapeutics (SRNE -9.21%) were skyrocketing 38.5% as of 12:24 p.m. EST on Wednesday. The huge gain came after the biotech announced positive preliminary results on Tuesday evening from its phase 1b study evaluating its COVI-MSC in treating COVID-19.

So what

The fortunes of small biotech stocks like Sorrento depend on good results from clinical studies of their pipeline candidates. And the results announced last night for COVI-MSC, its experimental stem cell therapy, were very good.

Older man in a hospital bed with a healthcare professional standing next to him

Image source: Getty Images.

Sorrento reported that the first three patients enrolled in its phase 1b study of COVI-MSC were discharged from the hospital within only one week of beginning infusions of the experimental therapy. These patients previously suffered from acute respiratory distress (ARD) or acute respiratory distress syndrome (ARDS) caused by COVID-19.

The company said that one of the patients had been in the hospital for three weeks before receiving COVI-MSC. Another of the patients had been previously discharged but had to be readmitted because of a recurrence of ARD. These patients and a third patient in Sorrento's study improved rapidly after infusions of COVI-MSC.

It's important to keep in mind, though, that these results are very early and only include a small number of patients. There's no guarantee that COVI-MSC will deliver such great results in a larger group of patients.

Now what

Sorrento hopes to advance COVI-MSC to a controlled phase 2 study. In the meantime, the company is seeking Emergency Use Authorization for its COVI-STIX antibody test for COVID-19, and is evaluating several other potential coronavirus therapies in clinical studies.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$2.07 (-9.21%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.